ES2421558T3 - Anticuerpos específicos de cáncer y proteínas de superficie celular - Google Patents

Anticuerpos específicos de cáncer y proteínas de superficie celular

Info

Publication number
ES2421558T3
ES2421558T3 ES05823959T ES05823959T ES2421558T3 ES 2421558 T3 ES2421558 T3 ES 2421558T3 ES 05823959 T ES05823959 T ES 05823959T ES 05823959 T ES05823959 T ES 05823959T ES 2421558 T3 ES2421558 T3 ES 2421558T3
Authority
ES
Spain
Prior art keywords
cell surface
surface proteins
specific cancer
cancer antibodies
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05823959T
Other languages
English (en)
Inventor
Nicholas Glover
Glen Macdonald
Joycelyn Entwistle
Jeannick Cizeau
Francina Chahal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Viventia Biotech Inc
Viventia Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viventia Biotech Inc, Viventia Biotechnologies Inc filed Critical Viventia Biotech Inc
Application granted granted Critical
Publication of ES2421558T3 publication Critical patent/ES2421558T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Una proteína aislada que comprende una variante asociada con cáncer del transportador de glucosa 8 expresadaen la superficie de células cancerosas que comprende la secuencia de aminoácidos de la SEC ID Nº: 11, 12 o 13 ouna variante funcional de las mismas.
ES05823959T 2004-12-21 2005-12-21 Anticuerpos específicos de cáncer y proteínas de superficie celular Expired - Lifetime ES2421558T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63744804P 2004-12-21 2004-12-21
PCT/CA2005/001953 WO2006066408A1 (en) 2004-12-21 2005-12-21 Cancer specific antibody and cell surface proteins

Publications (1)

Publication Number Publication Date
ES2421558T3 true ES2421558T3 (es) 2013-09-03

Family

ID=36601325

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05823959T Expired - Lifetime ES2421558T3 (es) 2004-12-21 2005-12-21 Anticuerpos específicos de cáncer y proteínas de superficie celular

Country Status (12)

Country Link
US (2) US8084576B2 (es)
EP (1) EP1833968B1 (es)
JP (2) JP5143566B2 (es)
CN (1) CN101160402B (es)
AU (1) AU2005318836B2 (es)
CA (1) CA2591768C (es)
ES (1) ES2421558T3 (es)
IL (1) IL183958A (es)
NZ (1) NZ556055A (es)
RU (1) RU2007127889A (es)
WO (1) WO2006066408A1 (es)
ZA (1) ZA200705837B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560278C (en) 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9636329B2 (en) * 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
PL3052525T3 (pl) * 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
KR101985215B1 (ko) * 2015-05-29 2019-06-03 후지필름 가부시키가이샤 폴리이미드 전구체 조성물, 감광성 수지 조성물, 경화막, 경화막의 제조 방법, 반도체 디바이스 및 폴리이미드 전구체 조성물의 제조 방법
US10781260B2 (en) 2016-08-08 2020-09-22 Sorrento Therapeutics, Inc. Anti-OX40 binding proteins
CN108101988B (zh) * 2016-11-24 2021-09-07 复旦大学 针对cd16的全人源单域抗体、其抗原结合片段及应用
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
WO2020086830A2 (en) * 2018-10-26 2020-04-30 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN114807054B (zh) * 2022-06-24 2022-09-13 北京索莱宝科技有限公司 小鼠抗人IgG单抗杂交瘤细胞株、抗体、抗体组合物及试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
JPH06141884A (ja) * 1992-11-06 1994-05-24 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
AU6162794A (en) 1993-01-22 1994-08-15 Hygeia Pharmaceuticals, Inc. Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
US6680296B1 (en) * 1997-06-06 2004-01-20 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
US20030228592A1 (en) * 1997-10-01 2003-12-11 St. Vincent's Institute Of Medical Research Human facilitative glucose transport protein GLUT8
AU5840300A (en) 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
WO2002099083A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Gfats as modifiers of the p53 pathway and methods of use
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン， インコーポレイテッド 癌処置のための組成物
WO2004095099A1 (en) * 2003-04-01 2004-11-04 Corning Incorporated Photonic band gap optical fiber

Also Published As

Publication number Publication date
US20100254982A1 (en) 2010-10-07
WO2006066408A1 (en) 2006-06-29
EP1833968B1 (en) 2013-04-17
CA2591768C (en) 2016-06-14
US20120128723A1 (en) 2012-05-24
EP1833968A1 (en) 2007-09-19
AU2005318836B2 (en) 2012-03-22
CA2591768A1 (en) 2006-06-29
NZ556055A (en) 2009-12-24
JP2013063066A (ja) 2013-04-11
JP2008523825A (ja) 2008-07-10
IL183958A (en) 2012-02-29
JP5143566B2 (ja) 2013-02-13
CN101160402A (zh) 2008-04-09
US8697075B2 (en) 2014-04-15
US8084576B2 (en) 2011-12-27
ZA200705837B (en) 2008-05-28
EP1833968A4 (en) 2009-09-16
RU2007127889A (ru) 2009-01-27
IL183958A0 (en) 2007-10-31
CN101160402B (zh) 2013-06-05
AU2005318836A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
HRP20090245T1 (en) Pyy agonists and uses thereof
WO2005030797A3 (en) Melanocortin receptor agonists
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
AR038568A1 (es) Anticuerpos anti-a beta y su uso
NO20063026L (no) Antistoffer
WO2003014303A3 (en) Molecular interactions in cells
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
WO2005047459A3 (en) Sars nucleic acids, proteins, antibodies, and uses thereof
EP1548107A4 (en) CHROMOPROTEIN AND FLUORO PROTEINS
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
ES2507094T3 (es) Proteína específica del timo
PT1276763E (pt) Proteinas anti-congelantes sua producao e utilizacao
WO2003089451A3 (en) Antibodies specific for mucin polypeptide
ATE316577T1 (de) Das goodpasture-antigen bindende protein
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
NO20081503L (no) T-celle adhesjonsmolekyl, og antistoff dertil
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
WO2004065554A3 (en) Human saa3 nucleic acid molecule, protein, and methods of use for same
WO2007039699A3 (fr) Substrat proteique pour la detection de l'activite calpaine 3
WO2005089509A3 (en) High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
WO2001025430A3 (en) Novel human membrane proteins
ES2311472T3 (es) Nuevos genes de control del ciclo celular y proteinas codificadas por los mismos.
MXPA05008925A (es) Ciclooxigenasa-3 humana y usos de la misma.
WO2005017109A3 (en) Nucleic acids and polypeptides required for cell survival in the absence of rb